There has been significant progress in the treatment of patients with advanced clear cell
renal cell carcinoma (ccRCC), with improved knowledge of disease biology and the …

Purpose Following curative treatment for localised renal cell carcinoma (RCC), up to 30% of
patients develop tumour recurrence. Prognostic scores are essential to guide individualised …

The TRIPOD (Transparent Reporting of a multivariable prediction model for Individual
Prognosis Or Diagnosis) Statement includes a 22-item checklist, which aims to improve the …

Summary Background The International Metastatic Renal-Cell Carcinoma Database
Consortium model offers prognostic information for patients with metastatic renal-cell …

Background The randomised phase 2 CABOSUN trial comparing cabozantinib with sunitinib
as initial therapy for advanced renal cell carcinoma (RCC) of intermediate or poor risk met …

Background Previous prognostic models for second-line systemic therapy in patients with
metastatic renal cell carcinoma have not been studied in the setting of targeted therapy. We …

Summary Background The Memorial Sloan Kettering Cancer Center (MSKCC) risk model is
an established prognostic tool for metastatic renal-cell carcinoma that integrates clinical and …

BACKGROUND This study aimed to apply the International mRCC Database Consortium
(IMDC) prognostic model in metastatic non–clear cell renal cell carcinoma (nccRCC). In …

Background Emerging evidences indicate that inflammation plays a crucial role in
carcinogenesis and tumor progression. Inflammatory response biomarkers are recognized …

Background: Tumor necrosis has been proposed as a marker of poor prognosis in a variety
of solid organ malignant tumor types. Despite this, its assessment has yet to be adopted into …